- Home
- RNP vs SLS Comparison
RNP vs SLS Comparison
Compare RNP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNP | SLS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.2M | 924.5M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | RNP | SLS |
|---|---|---|
| Price | $20.64 | $11.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 96.1K | ★ 9.6M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.27 | $1.39 |
| 52 Week High | $22.58 | $15.88 |
Technical Indicators
Market Signals| Indicator | RNP | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 47.72 |
| Support Level | $20.44 | $3.91 |
| Resistance Level | $20.95 | $15.88 |
| Average True Range (ATR) | 0.24 | 1.29 |
| MACD | 0.02 | -0.41 |
| Stochastic Oscillator | 81.63 | 11.07 |
Price Performance
Historical ComparisonAbout RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.